UnityPoint Health - Des Moines

Gastrointestinal Research Studies

Pancreatic

A021501: Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

R0848: Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

S1505:

A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine / nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma (temporarily suspended)


S1513: Phase II Study of 2nd Line FOLFIRI Vs. Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) in Metastatic Pancreatic Cancer

Rectal

GI002: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation Vs Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Hepatocellular

R1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Cancer Control

S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)